Home > News > 198/The response to sodium channel provocation in healthy subjects
Read Time: 2 mins

198/The response to sodium channel provocation in healthy subjects

Published Online: October 4th 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr198
Authors: BE Ensam (Presenting Author) – St Georges University of London, London, UK; SC Scrocco – St Georges University of London, London, UK; VB Batchvarov – St Georges University of London, London, UK; GF Finocchario – St Georges University of London, London, UK; SC Papatheodorou – St Georges University of London, London, UK; C Miles – St Georges University of London, London, UK; B Gray – St Georges University of London, London, UK; E Behr – St Georges University of London, London, UK
Quick Links:
Article Information

Abstract: Sodium channel blockade (SCB) is used to investigate those thought to be at risk of harbouring a concealed form of Brugada syndrome (BRS). Most frequently this includes those undergoing evaluation following cardiac arrest, or a premature sudden death or diagnosis of BRS in a relative. However, a recent consensus document advised that an isolated drug induced type 1 Brugada ECG pattern is no longer diagnostic of BRS. This followed identification of an ajmaline induced type 1 pattern in 4.5% of undefined controls in a small Turkish study. The primary objective of this study was not, however, the yield of SCB in health subjects. Thus, the precise yield of the type 1 pattern in systematically evaluated healthy subjects remains unknown.

Objective: To determine the yield of the drug induced type 1 pattern in systematically evaluated healthy subjects undergoing SCB with Ajmaline.

Methods: Potential volunteers responded to a national advertisement for healthy subjects. Following a comprehensive online screening questionnaire regarding personal and family history, eligible participants were invited to undergo pre-trial screening which involved a focussed cardiovascular history and examination, high-right-precordial-lead electrocardiography (HRPL-ECG) and transthoracic echocardiography (ECHO). Those with a pre-screening abnormality were excluded. Finally, eligible subjects underwent intravenous Ajmaline provocation using a standard protocol (1 mg/kg max 100 mg over 5 minutes) with continuous digital HRPL-ECG acquisition followed by a 24-hour ambulatory HRPL-ECG and a contrast enhanced cardiac magnetic resonance scan (CMR).

Results: From 340 online responses, 204 were deemed eligible based on the screening questionnaire and were invited for pre-trial screening. One-hundred-and-ten (110) subjects attended, of whom 100 were deemed eligible and underwent Ajmaline provocation. Three subjects (3/100 3%) developed the diagnostic type 1 BRS pattern (see Figure 1). A spontaneous type 1 pattern was not observed in any subject during ambulatory HRPL-ECG monitoring.

Conclusion: The yield of the ajmaline-induced type 1 Brugada ECG pattern in comprehensively screened healthy subjects is 3% (3/100). Robust revision of the diagnostic criteria for ajmaline challenge in BRS are necessary.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
43/Cardiac tamponade as a complication of transseptal puncture: associations and operatordependent variables during left atrial ablation at Barts Heart Centre
E Maclean (Presenting Author) - St Bartholomew’s Hospital, London; K Mahtani - St Bartholomew’s Hospital, London; C Butcher - St Bartholomew’s Hospital, London; N Ahluwalia - St Bartholomew’s Hospital, London; M Finlay - St Bartholomew’s Hospital, London; S Honarbakhsh - St Bartholomew’s Hospital, London; A Creta - St Bartholomew’s Hospital, London; A Chow - St Bartholomew’s Hospital, London; V Sawhney - St Bartholomew’s Hospital, London; V Ezzat - St Bartholomew’s Hospital, London; MJ Earley - St Bartholomew’s Hospital, London; M Dhinoja - St Bartholomew’s Hospital, London; S Sporton - St Bartholomew’s Hospital, London; MD Lowe - St Bartholomew’s Hospital, London; PD Lambiase - St Bartholomew’s Hospital, London; F Khan - St Bartholomew’s Hospital, London; SY Ahsan - St Bartholomew’s Hospital, London; RJ Hunter - St Bartholomew’s Hospital, London; RJ Schilling - St Bartholomew’s Hospital, London; O Sega - St Bartholomew’s Hospital, London Read Time: 2 mins

European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr43

Introduction: Cardiac tamponade is a high morbidity complication of transseptal puncture (TSP). We examined the incidence and predictors of TSP-related cardiac tamponade (TRCT) for all patients undergoing left atrial ablation at our centre from 2016-2020. Methods: Patient and procedural variables were extracted retrospectively. Cases of cardiac tamponade were scrutinised to adjudicate TSP culpability. Adjusted multivariate […]

  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72